These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 29110847)

  • 1. Symptomatic pseudo-progression followed by significant treatment response in two lung cancer patients treated with immunotherapy.
    Hochmair MJ; Schwab S; Burghuber OC; Krenbek D; Prosch H
    Lung Cancer; 2017 Nov; 113():4-6. PubMed ID: 29110847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
    Sul J; Blumenthal GM; Jiang X; He K; Keegan P; Pazdur R
    Oncologist; 2016 May; 21(5):643-50. PubMed ID: 27026676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.
    Carbognin L; Pilotto S; Milella M; Vaccaro V; Brunelli M; Caliò A; Cuppone F; Sperduti I; Giannarelli D; Chilosi M; Bronte V; Scarpa A; Bria E; Tortora G
    PLoS One; 2015; 10(6):e0130142. PubMed ID: 26086854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1 blockade in advanced NSCLC: A focus on pembrolizumab.
    Peters S; Kerr KM; Stahel R
    Cancer Treat Rev; 2018 Jan; 62():39-49. PubMed ID: 29156447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pembrolizumab for the treatment of non-small cell lung cancer.
    Muller M; Schouten RD; De Gooijer CJ; Baas P
    Expert Rev Anticancer Ther; 2017 May; 17(5):399-409. PubMed ID: 28338376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review.
    Sacher AG; Gandhi L
    JAMA Oncol; 2016 Sep; 2(9):1217-22. PubMed ID: 27310809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.
    Goldberg SB; Gettinger SN; Mahajan A; Chiang AC; Herbst RS; Sznol M; Tsiouris AJ; Cohen J; Vortmeyer A; Jilaveanu L; Yu J; Hegde U; Speaker S; Madura M; Ralabate A; Rivera A; Rowen E; Gerrish H; Yao X; Chiang V; Kluger HM
    Lancet Oncol; 2016 Jul; 17(7):976-983. PubMed ID: 27267608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer.
    Dang TO; Ogunniyi A; Barbee MS; Drilon A
    Expert Rev Anticancer Ther; 2016; 16(1):13-20. PubMed ID: 26588948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation.
    Zschäbitz S; Lasitschka F; Hadaschik B; Hofheinz RD; Jentsch-Ullrich K; Grüner M; Jäger D; Grüllich C
    Eur J Cancer; 2017 May; 76():1-7. PubMed ID: 28262583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiologic and autopsy findings in a case of fatal immune checkpoint inhibitor-associated pneumonitis.
    Shea M; Rangachari D; Hallowell RW; Hollie NI; Costa DB; VanderLaan PA
    Cancer Treat Res Commun; 2018; 15():17-20. PubMed ID: 30207283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy.
    Villaruz LC; Socinski MA
    Clin Pharmacol Ther; 2016 Sep; 100(3):212-4. PubMed ID: 27090296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excellent treatment response with pembrolizumab in a lung cancer patient who developed immune-mediated acute motor/sensory axonal polyneuropathy.
    Yen CC; Su HC; Chu CY; Lai SJ; Yan JJ; Su WP; Su WC
    Lung Cancer; 2018 Jun; 120():149-151. PubMed ID: 29681404
    [No Abstract]   [Full Text] [Related]  

  • 13. Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer.
    McDermott J; Jimeno A
    Drugs Today (Barc); 2015 Jan; 51(1):7-20. PubMed ID: 25685857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma.
    Guibert N; Mazieres J; Delaunay M; Casanova A; Farella M; Keller L; Favre G; Pradines A
    Oncotarget; 2017 Jun; 8(23):38056-38060. PubMed ID: 28445137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central Nervous System Pseudoprogression in a Patient Treated with PD-1 Checkpoint Inhibitor.
    Doherty MK; Jao K; Shepherd FA; Hazrati LN; Leighl NB
    J Thorac Oncol; 2015 Oct; 10(10):e100-1. PubMed ID: 26398825
    [No Abstract]   [Full Text] [Related]  

  • 16. PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data.
    Aguiar PN; De Mello RA; Hall P; Tadokoro H; Lima Lopes G
    Immunotherapy; 2017 May; 9(6):499-506. PubMed ID: 28472902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies.
    Azpilikueta A; Agorreta J; Labiano S; Pérez-Gracia JL; Sánchez-Paulete AR; Aznar MA; Ajona D; Gil-Bazo I; Larrayoz M; Teijeira A; Rodriguez-Ruiz ME; Pio R; Montuenga LM; Melero I
    J Thorac Oncol; 2016 Apr; 11(4):524-36. PubMed ID: 26845193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitors in lung cancer: an update.
    Sullivan K; Preeshagul I; Budman D; Seetharamu N
    Future Oncol; 2017 May; 13(11):955-959. PubMed ID: 28481150
    [No Abstract]   [Full Text] [Related]  

  • 19. The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies.
    Ciccarese C; Iacovelli R; Bria E; Modena A; Massari F; Brunelli M; Fantinel E; Bimbatti D; Zamboni GA; Artibani W; Tortora G
    Immunotherapy; 2017 Jun; 9(7):579-587. PubMed ID: 28595514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
    Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
    Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.